GE Healthcare (NYSE:GE) and Golden Meditech said this week they inked a strategic collaboration deal to provide GE’s integrated and automated digital systems and solutions to Golden Meditech for use in its umbilical cord blood cryopreservation processes.
Hong Kong-based Golden Meditech said that umbilical cord blood contains rich hematopoietic stem cells which could facilitate reconstruction of hematopoietic and immune systems with possible applications in stem cell transplantation and other treatments.
Through the partnership, Golden Meditech will use fully automated cell processing systems and associated tools and kits to meet requirements for cord blood processing, according to a press release.
In September, GE Healthcare said it won FDA 510(k) clearance for its Senographe Pristina Dueta, which it claims is the 1st patient-assisted mammography device that allows women to control their own compression during the examination.
